Research programme: immunotherapy - sigma-tau

Drug Profile

Research programme: immunotherapy - sigma-tau

Alternative Names: Pentraxin 3; PTX 3

Latest Information Update: 23 Aug 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sigma-tau SpA
  • Class Proteins
  • Mechanism of Action Complement activation stimulants; Cytokine stimulants; Cytomegalovirus replication inhibitors; Transcription factor stimulants; Viral fusion protein inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Aspergillosis; Cytomegalovirus infections

Most Recent Events

  • 04 Jun 2008 Development of PTX3 is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top